Brilique 90 mg film-coated tablets clinical trials
6 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
Dual Antithrombotic Therapy with Dabigatran and Ticagrelor in Patients with Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)
This study looks at a new way to prevent blood clots and bleeding in people who have had a heart attack or similar heart problem and also have an irregular heartbeat, after having a heart procedure. It compares different doses of a blood-thinning medicine.
For: Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary InterventionPoland - Ongoing, recruitingTherapeutic use (Phase IV)
Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy (TARGET-FIRST)
This study looks at different blood-thinning medicines given after a heart attack to see which combinations best prevent serious problems like another heart attack, stroke, or severe bleeding. It's for adults of all ages, men and women, who have recently had a heart attack.
For: Acute Myocardial InfarctionSpain · Netherlands · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
Ticagrelor monotherapy after coronary stenting in patients with acute myocardial infarction - A prospective single-centre, single-arm phase II study
This study looks at people who've had a heart attack and a stent fitted. Researchers are testing a drug called Brilique to see if it can prevent further heart problems like another heart attack or blood clots in the stent, within three months.
For: Myocardial infarctionSweden - Ongoing, recruitingTherapeutic use (Phase IV)
Pharmacodynamic Outcomes in patients with coronary artery disease undergoing Percutaneous coronary intervention treated with an individualized treatment STRATEGY (POPular STRATEGY PD)
This study looks at different blood-thinning medicines for people who have had a heart procedure called a stent. Researchers want to see which medicine works best to prevent blood clots while also checking for any bleeding, to help doctors choose the right treatment for each patient.
For: Stable coronary artery disease · Chronic coronary syndromeNetherlands - AuthorisedTherapeutic use (Phase IV)
PhARMacodynamics of earlY versus Delayed Administration of TIcagrelor during CAngrelor infusion in patients with acute ST-segment elevation Myocardial Infarction: a randomized superiority study
This study compares when to give a key heart medication (ticagrelor) after another (cangrelor) in people having a heart attack. We're checking if giving it earlier helps prevent blood clots better, and looking at important heart events and bleeding.
For: ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)Italy - AuthorisedTherapeutic use (Phase IV)
COATS (genetic Clopidogrel response testing to finetune the antithrombotic regimen in (D)OAC Treated patients undergoing PCI) Study
This study looks at two common blood-thinning medications, Ticagrelor (Brilique) and Clopidogrel, in patients with heart artery disease undergoing a procedure to widen their arteries (PCI). It explores how effective and safe these drugs are, especially when a genetic test might help guide which one to use.
For: Patients with coronary artery disease and an indication for PCINetherlands